Efficacy and safety of intensity Modulated Radiation therapy combined with Concurrent Chemoradiotherapy in the treatment of Recurrent Cervical Cancer

Objective: To evaluate the clinical value of intensity modulated radiation therapy (IMRT) combined with concurrent chemoradiotherapy in the treatment of recurrent cervical cancer. Methods: This was a retrospective study. Eighty patients with recurrent cervical cancer were recruited and randomly divided into two groups: the experimental group and the control group, with 40 cases in each group at The Fourth Hospital of Hebei Medical University from April, 2017 to April, 2022. Patients in the control group were only given IMRT, while those in the experimental group were given concurrent chemoradiotherapy with paclitaxel and cisplatin based on IMRT. All patients were evaluated for clinical efficacy, adverse drug reactions, and differences in the levels of SCC-Ag, CEA and CA724 and other tumor markers before and after treatment. Results: The total effective rate in the experimental group was significantly better than in the control group (p=0.02). The incidence of adverse reactions was 40% in the experimental group and 32.5% in the control group, with no statistically significant difference (p=0.48). After treatment, the levels of tumor markers in the experimental group were significantly lower than those in the control group, with a statistically significant difference (p=0.00). The three years survival rate was 80% in the experimental group and 55% in the control group (p=0.03). The five years survival rate was 65% in the experimental group and 42.5% in the control group, with a statistically significant difference (p=0.04). Conclusion: Intensity modulated radiation therapy (IMRT) combined with concurrent chemoradiotherapy is a safe and effective regimen for recurrent cervical cancer, boasting significant clinical efficacy, reduced tumor markers, no significant increase in adverse reactions, and significantly improved three-years and five years survival rate.

[1]  S. Kabekkodu,et al.  Molecular landscape of recurrent cervical cancer. , 2020, Critical reviews in oncology/hematology.

[2]  I. Inoue,et al.  APOBEC: A molecular driver in cervical cancer pathogenesis , 2020, Cancer Letters.

[3]  B. Erickson,et al.  NRG Oncology /RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer- An Update. , 2020, International journal of radiation oncology, biology, physics.

[4]  Qin Chen,et al.  Combined Evaluation of Preoperative Serum CEA and CA125 as an Independent Prognostic Biomarker in Patients with Early-Stage Cervical Adenocarcinoma , 2020, OncoTargets and therapy.

[5]  N. Colombo,et al.  Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy , 2020, International Journal of Gynecological Cancer.

[6]  Young Seok Kim,et al.  Significance of the number of high-risk factors in patients with cervical cancer treated with radical hysterectomy and concurrent chemoradiotherapy. , 2020, Gynecologic oncology.

[7]  N. Kadoya,et al.  Clinical experience of pelvic radiotherapy or chemoradiotherapy for postoperative uterine cervical cancer using intensity-modulated radiation therapy , 2020, Journal of radiation research.

[8]  D. Parkin,et al.  Definitive chemoradiotherapy for cervical cancer: A 11-year population-based study. , 2020, European journal of cancer care.

[9]  M. Soares,et al.  The Role of the Cervicovaginal Microbiome on the Genesis and as a Biomarker of Premalignant Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer , 2019, International journal of molecular sciences.

[10]  I. Francis,et al.  A Radiologist's Guide to Response Evaluation Criteria in Solid Tumors. , 2019, Current problems in diagnostic radiology.

[11]  Meng Li,et al.  Adjuvant chemoradiotherapy versus radiotherapy in cervical cancer patients with intermediate-risk factors: A systematic review and meta-analysis. , 2019, European journal of obstetrics, gynecology, and reproductive biology.

[12]  H. Banerjee,et al.  Human Papilloma Virus-Associated Cervical Cancer and Health Disparities , 2019, Cells.

[13]  M. Dimopoulos,et al.  Systemic therapy in cervical cancer: 30 years in review. , 2019, Critical reviews in oncology/hematology.

[14]  P. Grigsby,et al.  Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. , 2019, International journal of radiation oncology, biology, physics.

[15]  E. Tharavichitkul,et al.  A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial , 2019, Journal of gynecologic oncology.

[16]  Kathleen R. Cho,et al.  Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  N. Ramaiya,et al.  Overview of systemic treatment in recurrent and advanced cervical cancer: a primer for radiologists , 2018, Abdominal Radiology.

[18]  Junbo Hu,et al.  Clinical Value of Combining 18F-FDG PET/CT and Routine Serum Tumor Markers in The Early Detection of Recurrence Among Follow-up Patients Treated for Cervical Squamous Cell Carcinoma , 2018, Journal of Cancer.

[19]  N. Kariman,et al.  Educational Interventions for Cervical Cancer Screening Behavior of Women: A Systematic Review , 2018, Asian Pacific journal of cancer prevention : APJCP.

[20]  L. Kumar,et al.  Chemotherapy and targeted therapy in the management of cervical cancer. , 2018, Current problems in cancer.

[21]  P. Vedsted,et al.  Cervical Cancer Prevalence, Incidence and Mortality in Low and Middle Income Countries: A Systematic Review , 2018, Asian Pacific journal of cancer prevention : APJCP.

[22]  A. Sasse,et al.  Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer , 2017, International Journal of Gynecologic Cancer.

[23]  J. Murdoch,et al.  Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage IB2 cervical cancer. , 2015, The Cochrane database of systematic reviews.

[24]  N. Aziz,et al.  Pattern of presentation of cervical carcinoma at Nuclear Institute of Medicine and Radiotherapy, Pakistan , 2013, Pakistan journal of medical sciences.

[25]  W. Kong,et al.  Efficacy and prognostic factors of concurrent chemoradiotherapy in patients with stage Ib3 and IIa2 cervical cancer. , 2020, Ginekologia polska.